Broadfin Healthcare Master Fund Ltd is 10% Owner at Recro Pharma, Inc. (REPH). They have made 16 open-market trades across 6 companies since 2016, most recently 2022-02-11.
4 open-market purchases totalling $7.9M since 2016, against 12 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 58% | 67% |
| Avg Move | +0.6% | -2.3% | -3.6% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BDSI | BUY | 2021-05-11 | 2021-05-13 | $3.20 | $961K | -0.6% | +5.5% | +6.1% |
| BDSI | SELL | 2019-11-15 | 2019-11-19 | $6.00 | $39.0M | +13.1% | +5.9% | -13.1% |
| REPH | SELL | 2017-12-12 | 2017-12-14 | $9.84 | $1.5M | -0.8% | -8.4% | +14.5% |
| REPH | SELL | 2017-12-05 | 2017-12-07 | $10.00 | $1.0M | +0.6% | -10.6% | +13.6% |
| PETX | SELL | 2017-11-29 | 2017-12-01 | $5.98 | $2.8M | +4.0% | -4.0% | -29.7% |
| REPH | SELL | 2017-11-28 | 2017-11-30 | $9.62 | $463K | -1.1% | -6.6% | -6.9% |
| REPH | SELL | 2017-11-24 | 2017-11-24 | $9.37 | $55K | +2.1% | +3.0% | -7.6% |
| REPH | SELL | 2017-11-22 | 2017-11-24 | $9.37 | $455K | +2.1% | +3.0% | -7.6% |
| REPH | SELL | 2017-11-21 | 2017-11-24 | $9.45 | $1.6M | +2.1% | +3.0% | -7.6% |
| CORI | SELL | 2017-11-16 | 2017-11-17 | $10.95 | $4.8M | +2.9% | -3.8% | +9.9% |
| CORI | SELL | 2017-11-02 | 2017-11-03 | $11.05 | $1.7M | -9.7% | +0.4% | +12.1% |
| CORI | SELL | 2017-10-04 | 2017-10-06 | $11.01 | $2.4M | -9.2% | -2.2% | -9.1% |
| AVDL | SELL | 2017-06-22 | 2017-06-26 | $10.68 | $2.8M | +1.3% | -7.5% | -11.6% |
| REPH | BUY | 2016-12-13 | 2016-12-14 | $6.00 | $3.9M | +7.9% | +9.2% | +16.9% |
| AEGR | BUY | 2016-09-13 | 2016-09-14 | $1.75 | $131K | +48.0% | +16.8% | N/A |
| REPH | BUY | 2016-08-16 | 2016-08-17 | $7.50 | $2.9M | +11.9% | +12.7% | -6.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.